Breast Cancer Vaccine Closer than You Think

Developing a breast cancer vaccine has been the work of researchers at Cleveland

Clinic’s Lerner Research Institute and a new company created from the institute,

Shield Biotech.  They found that a single vaccine could prevent breast tumors from

occurring in mice genetically bred to develop breast cancer.  The vaccine could also

inhibit the growth of already existing breast tumors.    Phase 1 trials of the drug are

expected to begin within two years in humans and be completed  in about three  years

from their start. Phase 1 trials which will involve women with triple negative breast

cancer who have recovered from current standard of care treatment.  The trial will

determine the safety and optimum dose to stimulate an immune response.

For further information regarding breast cancer trials visit the NIH’s

www.clinicaltrials.gov.  For more information on this trial go to pinkvaccine@ccf.org

 

Related Posts

Tags

Share This